Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
RESEARCH TOOLSreports
Holding CLSD?
Track your performance easily
CLSD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.80 - $2.12
Previous CloseN/A
Volume106.43K
Average Volume (3M)295.75K
Market Cap
$73.78M
Enterprise Value$121.31M
Total Cash (Recent Filing)$83.63M
Total Debt (Recent Filing)$7.59M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Mar 18, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding75,843,506
10 Day Avg. Volume278,896
30 Day Avg. Volume295,752
Standard Deviation0.23
R-Squared0.25
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.70
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.64
Enterprise Value/Revenue15.75
Enterprise Value/Gross Profit15.41
Enterprise Value/Ebitda-4.49
Forecast
1Y Price Target
$6.20Price Target Upside539.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Clearside Biomedical News
PremiumCompany Announcements
Clearside Biomedical Highlights Advancements in Drug DeliveryPremiumCompany Announcements
Clearside Biomedical Reports Positive Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyCLS-AX met all efficacy endpoints in Ph2b ODYSSEY trial in wet AMD, with no severe or serious safety signals.
Market ValuationConsidering current levels, CLSD appears highly undervalued compared to peers.
Treatment DurabilityWith a 4-month rescue-free rate of 90%, CLS-AX is potentially more durable than standard of care therapies.
Bears Say
Financial OverhangThe company will need to address its financial overhang for shares to reflect the potential of CLS-AX in wet AMD.
Investor ConcernsA few cases of mild inflammation in the ODYSSEY trial left some investors nervous.
Share PerformanceShares have been under pressure due to concerns related to four cases of mild intraocular inflammation.
---
Ownership Overview
16.43% Insiders
4.88% Mutual Funds
5.06% Other Institutional Investors
69.78% Public Companies and Individual Investors
CLSD FAQ
What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $0.80 and its highest was $2.12 in the past 12 months.
What is Clearside Biomedical’s market cap?
Clearside Biomedical’s market cap is $73.78M.
When is Clearside Biomedical’s upcoming earnings report date?
Clearside Biomedical’s upcoming earnings report date is Mar 18, 2025 which is in 68 days.
How were Clearside Biomedical’s earnings last quarter?
Clearside Biomedical released its earnings results on Nov 12, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.124 by $0.024.
Is Clearside Biomedical overvalued?
According to Wall Street analysts Clearside Biomedical’s price is currently Undervalued.
Does Clearside Biomedical pay dividends?
Clearside Biomedical does not currently pay dividends.
What is Clearside Biomedical’s EPS estimate?
Clearside Biomedical’s EPS estimate is -0.1.
How many shares outstanding does Clearside Biomedical have?
Clearside Biomedical has 75,843,506 shares outstanding.
What happened to Clearside Biomedical’s price movement after its last earnings report?
Clearside Biomedical reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.124. Following the earnings report the stock price went down -2.703%.
Which hedge fund is a major shareholder of Clearside Biomedical?
Currently, no hedge funds are holding shares in CLSD
---
Clearside Biomedical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.20 (539.18% Upside)
$6.20 (539.18% Upside)
Insider Transactions
Bought Shares
Worth $36.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.54%
12-Months-Change
Fundamentals
Return on Equity
91.63%
Trailing 12-Months
Asset Growth
-15.28%
Trailing 12-Months
Company Description
Clearside Biomedical
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
---
CLSD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strategic partnerships, and financial stability. The positive results from the ODYSSEY trial and strategic collaborations provide a strong foundation for future developments. However, there are uncertainties related to the Phase III plans and geographic atrophy research timeline.Read More>---
CLSD Stock 12 Month Forecast
Average Price Target
$6.20
▲(539.18% Upside)
Technical Analysis
ADMA Biologics
―
Cardiff Oncology
―
EyePoint Pharmaceuticals
―
Eyenovia
―
Ocular Therapeutix
―
Outlook Therapeutics
―
Best Analysts Covering CLSD
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
-1.23%
reiterated a buy rating 2 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -1.23% per trade.
---